Pharmicell Co. Ltd.

Products

Category

Product

Brand

Description

Global Market for Cell and Gene Therapy (BIO225B)

Cellgram-AMI		CellGram-AMI is a stem cell drug that approved by the Ministry of Foods and Drug Safety of Korea in 2011. At that time it was called Hearticellgram-AMI. It is manufactured using autologous bone marrow-derived mesenchymal stem cells. It is indicated for patients with acute myocardial infarction.
Cellgram-AKI		CellGram-AKI is an allogeneic mesenchymal stem cell therapy for the treatment of COVID-19. In 2020 it received temporary approval to treat severe pneumonia in COVID-19 patients.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment